Download Unicorn Signals App

Powered By EquityPandit
 Signals, Powered By  EquityPandit
MARKETS

Stocks in Focus: IDFC First Bank, Infosys, Religare Enterprises, and Others

Picture Source: Internet

The GIFT Nifty futures, which is an early indicator of the Nifty50 index, was trading 0.26% higher by 68 points at 26,058 indicating that the domestic benchmark indices are likely to make a positive start on Thursday. 

On Wednesday, 25 September, Domestic benchmark indices S&P BSE Sensex slipped 256 points or 0.30% to end at 85,169.87 while the Nifty50 traded 63.75 points higher or 0.25% and settled at 26,004.

Here are some stocks that are likely to remain in focus on 26 September.

IDFC First Bank: The company has received approval from the National Company Law Tribunal (NCLT), Chennai for merging IDFC Financial Holding Company with IDFC and their merger into IDFC First Bank. 

Infosys: The company has collaborated with Polestar, which is a Swedish electric performance car brand to create a base for the latter’s development of in-car infotainment, user experience, software and electrical/electronics engineering, and cloud-powered digital services.

Religare Enterprises: The executive chairperson of the company, Rashmi Saluja has got in touch with the Ministry of Finance and Prime Minister’s Office for intervention amid allegations made by the Securities and Exchange Board of India (SEBI) and Enforcement Directorate (ED). 

Vedanta: The board of directors of the company are set to meet on 8 October to consider and approve the fourth interim dividend for the fiscal year 2025. 

Oil India: The is weighing their options to start activities in Nagaland and is in discussion with the state and central government for the same. Moreover, the company is also looking to start oil production at its block in Gabon in central Africa during the next fiscal year. 

PB Fintech: The company has announced their plans to venture into the healthcare business by establishing its own chain of hospitals. 

Biocon: The company’s arm, Biocon Biologics has announced a positive outcome for Phase-III clinical study for its biosimilar of adalimumab and ustekinumab at the EADV Congress 2024.

Titan: The company’s fragrance division has announced the launch of a new affordable line of perfumes, 24Seven, targeting younger generations. 

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!

Get Daily Prediction & Stocks Tips On Your Mobile